Streetbeat News

Regulatory

OS

OneStream, Inc. has achieved FedRAMP High authorization for its government community cloud, meeting rigorous federal security standards.

Portfolio Pulse from

March 20, 2025 | 1:15 pm

VEJIF

Veji Holdings Ltd. (VEJI.X) trading is halted due to a fundamental change under CSE Policy 8, pending documentation review.

Portfolio Pulse from

March 20, 2025 | 1:00 pm

AAPL

GOOGL

The European Commission has accused Alphabet's Google and Apple of antitrust violations as part of its digital antitrust rules enforcement, amid ongoing trade tensions between the EU and the US.

Portfolio Pulse from

March 20, 2025 | 1:00 pm

VEJIF

Veji Holdings Ltd. (VEJI.X) trading is halted on the CSE due to a pending review of documentation related to a fundamental change as per CSE Policy 8.

Portfolio Pulse from

March 20, 2025 | 1:00 pm

CVX

President Trump is considering extending Chevron's license to produce oil in Venezuela, which was initially set to expire on April 3. This decision could impact Chevron's operations and its stock price.

Portfolio Pulse from

March 20, 2025 | 1:00 pm

DJI

NDX

SPX

US indices, including NASDAQ 100, Dow Jones 30, and S&P 500, experienced a rough overnight session. Investors are focused on the Federal Reserve's upcoming statement and potential actions by Jerome Powell to stabilize the market.

Portfolio Pulse from

March 20, 2025 | 1:00 pm

AMIX

Autonomix Medical, Inc. has been granted a U.S. patent for its proprietary catheter-based technology, enhancing its global patent portfolio. This technology aims to improve targeting and treatment of overactive nerves, potentially improving patient outcomes.

Portfolio Pulse from

March 20, 2025 | 12:45 pm

ABVE

Above Food Ingredients Inc. (NASDAQ: ABVE) is restructuring to focus on Agri-Tech and Fin-Tech sectors, leading to the winding up of its Purely Canada Food Corp. subsidiaries, which have been placed into receivership.

Portfolio Pulse from

March 20, 2025 | 12:45 pm

ICCM

IceCure Medical Ltd. is in ongoing discussions with the FDA for De Novo marketing authorization of its ProSense® cryoablation technology for early-stage breast cancer treatment.

Portfolio Pulse from

March 20, 2025 | 12:45 pm